Dexmedetomidine Levels in Breast Milk: Analysis of Breast Milk Expressed During and After Awake Craniotomy.
Sarah E DoddLindsay R Hunter GuevaraPalika DattaKathleen Rewers-FelkinsTeresa BakerThomas W HalePublished in: Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine (2021)
Background: Dexmedetomidine is an α2-adrenoreceptor agonist with utility in sedation and analgesia for the perioperative or intensive care patient. The literature regarding the safety of dexmedetomidine in lactating patients is very limited. Methods: We present a case of a lactating patient who received dexmedetomidine bolus and infusion as part of her intraoperative sedation during an awake craniotomy. Breast milk samples were expressed by the patient twice intraoperatively and twice postoperatively. All samples collected were analyzed using liquid chromatography mass spectrometry. Results: Dexmedetomidine concentrations in the breast milk were measured at various intervals and were 88 and 50 pg/mL intraoperatively, and 89 and 15 pg/mL postoperatively. Conclusion: Levels of dexmedetomidine in breast milk were exceedingly low. Interruption of breastfeeding and/or discarding expressed breast milk may not be necessary after dexmedetomidine in breastfeeding mothers. Further investigation with a larger sample size is warranted to describe safety profile of dexmedetomidine in breastfeeding infants.
Keyphrases
- cardiac surgery
- mass spectrometry
- liquid chromatography
- acute kidney injury
- preterm infants
- case report
- systematic review
- end stage renal disease
- patients undergoing
- chronic kidney disease
- low dose
- newly diagnosed
- ejection fraction
- deep brain stimulation
- prognostic factors
- dairy cows
- patient reported outcomes
- high resolution mass spectrometry
- chronic pain
- mechanical ventilation
- acute respiratory distress syndrome
- high performance liquid chromatography